Pathogenomix Inc.

4:45 PM - 5:00 PM (PDT), Wednesday, June 15, 2022
Pathogenomix is the leading NGS pathogen identification platform in the US. We've just received a Breakthrough Device Designation from FDA for our direct from whole blood + CSF pathogen identification platform, via the work generated from our development partnership with Mayo Clinic. Pathogenomix's goal is to lead the untapped point-of-care NGS identification market, as the first FDA approved broad-based NGS pathogen identification platform. Covid has penetrated sequencers into the hospital microbiology labs of the US. We've processed over 400,000 clinical samples as the bioanalytics backend for the top send-out reference labs in the US and Europe, and are now looking to provide this service directly to sequencer capable hospital labs. We want hospitals and critically ill patients to stop losing a day of turn-around-time to shipping out their samples.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Executive Chairman